Obinutuzumab (Gazyva) for Lupus Nephritis
The Medical Letter on Drugs and Therapeutics · 16.03.2026 · 68 (1750) · 46-47
DOI: 10.58347/tml.2026.1750c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 16.03.2026.
Abstract (Originalsprache)
Obinutuzumab (Gazyva – Genentech), a CD20-directed monoclonal antibody, has been approved by the FDA for treatment of adults with active lupus nephritis who are receiving standard treatment. It was previously approved for treatment of chronic lymphocytic leukemia and follicular lymphoma. Obinutuzumab is the third drug to be approved in the US for treatment of lupus nephritis; the oral calcineurin inhibitor voclosporin (Lupkynis) and the parenteral B-lymphocyte stimulator (BlyS)-specific inhibitor belimumab (Benlysta) were approved earlier.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Obinutuzumab (Gazyva) for Lupus Nephritis. The Medical Letter on Drugs and Therapeutics, 68(1750), 46-47. https://doi.org/10.58347/tml.2026.1750c
Vancouver
Obinutuzumab (Gazyva) for Lupus Nephritis. The Medical Letter on Drugs and Therapeutics. 2026;68(1750):46-47. doi:10.58347/tml.2026.1750c
BibTeX
@article{euvimed2026,
title = {Obinutuzumab (Gazyva) for Lupus Nephritis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1750},
pages = {46--47},
doi = {10.58347/tml.2026.1750c}
}
EUVIMED